Pfizer (PFE) Announces VIZIMPRO Receives MAA in EU for First-Line Treatment of Adult Patients with EGFR-Mutated NSCLC
Tweet Send to a Friend
(Updated - April 3, 2019 9:44 AM EDT)Pfizer Inc. (NYSE: PFE) today announced that the European Commission has approved VIZIMPRO® ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
